Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATB-346 low dose · 1 trial · 1 indication
Self reported pain intensity over the past 48 hours. Each item is scored 0-10 (0 = no pain; 10 = pain as bad as can be), yielding a total between 0 and 50
| Arm | Type | Description |
|---|---|---|
| Placebo Comparator | ACTIVE_COMPARATOR | ATB-346 150 mg overencapsulated tablet taken by mouth once daily for 14 days |
| ATB-346 mid-dose | ACTIVE_COMPARATOR | ATB-346 200 mg overencapsulated tablet taken by mouth once daily for 14 days |
| ATB-346 standard dose | ACTIVE_COMPARATOR | ATB-346 250 mg overencapsulated tablet taken by mouth once daily for 14 days |
| Active Comparator | PLACEBO_COMPARATOR | Overencapsulated placebo tablet taken by mouth once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| ATB-346 low dose | DRUG | Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients |
| Placebo | OTHER | Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients |
| ATB-346 mid-dose | DRUG | Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients |
| ATB-346 standard dose | DRUG | Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients |
Inclusion Criteria: * Diagnosis greater than 2 years duration requiring the use of regular therapies, e.g. oral or topical anti-inflammatories, acetaminophen, topical capsaicin * Between the ages of 40 to 75 * BMI ≤40 * Patients must be unlikely to procreate or agree to the use of acceptable contra...
ATB-346 low dose is an investigational small molecule being studied for the treatment of osteoarthritis, a degenerative joint disease. It is being developed by cbdMD, Inc. (ticker: YCBD). The drug is currently in Phase 2 clinical development for this indication.
ATB-346 low dose is being developed by cbdMD, Inc., a company traded on the stock market under the ticker YCBD. The company is conducting clinical research to evaluate the drug's efficacy and safety in patients with osteoarthritis.
ATB-346 low dose is in Phase 2 clinical development. A Phase 2 trial has been completed, which was a randomized, double-blind, placebo-controlled study involving 381 participants with osteoarthritis. The drug is not yet approved and remains investigational.
ATB-346 low dose has one completed clinical trial, identified as NCT03978208, titled "Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients." This Phase 2 study enrolled 381 participants in Canada and was randomized, double-blind, and placebo-controlled.
ATB-346 low dose is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for osteoarthritis. A Phase 2 trial has been completed, but the drug has not yet received regulatory approval for any use.